NewLink Genetics (NLNK) Posts Q2 Loss of 49c/Share

NewLink Genetics (NASDAQ: NLNK) reported Q2 EPS of ($0.49), $0.21 better than the analyst estimate of ($0.70). Revenue for the quarter came in at $7.45 million versus the consensus estimate of $4.32 million.

Cash Position: NewLink Genetics ended the quarter on June 30, 2015, with cash and equivalents totaling $207.6 million, compared to $202.8 million for the year ending December 31, 2014.

Financial Guidance

NewLink Genetics expects to have more than $160 million in cash and equivalents on December 31, 2015.

For earnings history and earnings-related data on NewLink Genetics (NLNK) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c